Q1 2025 Puma Biotechnology Inc Earnings Call Transcript

May 8, 2025 / 08:30 PM GMT

Release Date Price: $3.07 (+2.68%)

Transcript 10-Q8-K

Key Points

Positve

Puma Biotechnology Inc (PBYI) reported total revenue of $46.0 million for Q1 2025, showing an increase from $40.3 million in Q1 2024.
New prescriptions (NRX) increased by approximately 6% compared to Q4 2024.
The company is actively expanding its commercial reach, with new distribution agreements in Eastern Europe and Central Asia.
Puma Biotechnology Inc (PBYI) is conducting promising clinical trials, including a phase 1 trial showing encouraging results in patients with advanced pancreatic cancer.
The company is focused on diversifying its portfolio by evaluating potential in-licensing or acquisition opportunities.

Negative

Product revenue net decreased from $54.4 million in Q4 2024 to $43.1 million in Q1 2025.
There was a significant inventory decrease of approximately $4.7 million at specialty pharmacies and distributors.
Total prescriptions (TRX) declined by approximately 9% quarter over quarter.
The company reported a decrease in net income from $19.3 million in Q4 2024 to $3 million in Q1 2025.
Puma Biotechnology Inc (PBYI) anticipates lower royalty revenue in 2025 due to fewer shipments expected to China.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PBYI.OQ - Puma Biotechnology Inc
Q1 2025 Puma Biotechnology Inc Earnings Call
May 08, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon. My name is Sherry, and I will be your conference call operator today. At this time, all participants are in a listen-only mode. After the speaker's formal remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press the star key, then the number 1 on your telephone keypad. If you would like to withdraw your questions, please press 2.

If you should require operator assistance during the conference, please press 0. As a reminder, this call is being recorded. I would now like to turn the conference over to Mary Ann O'Hannison, senior director of investor relations for Puma Biotechnology.

Thank you may begin your conference.

-------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.